Tumori Journal Abstract Book - October 2020 - 200

200
work planning is lacking, whereas the consideration of the
private life changes for the best for all patients.
Conclusions: These preliminary data, although relative to
a very small sample, provides promising prerequisites to
attain a questionnaire to validate for the use in clinical
practice. The study is ongoing.

Tumori Journal 106(2S)
(BMI), tumors and risk of relapse. An individual nutritionalcouseling, targeted to weight management and to risk
factors control, may represent an important moment for
cancer patients at the follow-up visit focusing the relationship between dietary habits and risk of relapse.

T47
T46
INDIVIDUAL NUTRIZIONAL COUNSELING
IN CANCER PATIENTS DURING FOLLOWUP PERIOD: FIRST OPPORTUNITY FOR
THE PRACTIOTIONER TO REDUCE RISK
FACTORS
Cervo G.L.1, Alberti B.1, Salerno L.O.2, Di Pinto G.1
1

Oncologia Medica - Spoke Castrovillari - ASP Cosenza, Castrovillari;
Oncologia Medica - Spoke Paola - ASP Cosenza, Paola

Background: Nutritional counseling during follow-up visits can represent a valid opportunity to investigate lifestyle
and dietary habits of cancer patients in order to propose
nutritional indications for a reduction of the potential risks
of relapse. The main objective is to modify the lifestyle of
colo-rectal and breast cancer patients in follow-up through a
weight management. The aim of this study was to investigate the effect of individual dietary counseling of colo-rectal
and breast cancer patients during a 2 year follow-up period.
Materials and Methods: The study has been conducted
on 135 colorectal and breast cancer patients of both sexes
consecutively recruited from the oncology unit during
their first follow-up visit in the period between november
2017 and november 2019. An anamnestic questionnaire
about dietary habits and lifestyle were administred and the
main anthropometric measurements (weight, height, waist
and hip circumferences, bmi) were assessed. All patients
received two type of interventions: standard reccomendations about healthy lifestyle and nutritional counseling
based on mediterranean diet. Patients were stratified in 4
groups according to the WHO BMI classification.
Results: Among 76 colorectal cancer patients, 9% had
underweight, 33% had normal weight, whereas an overweight and obesity was detected in 19% and 39%. Among
56 subject in the breast cancer group bmi was respectively
0%, 21%, 14% and 65%. At the second follow-up visit,
patient with colorectal cancer showed a reduction of overweight and obese (14% e 5%) group and a median reduction of waist measurements di 9 cm (3-29 cm). For breast
cancer patients, the reduction of overweight and obese
groupe was 3% and 15% and the waist circumferences
showed a median decrease of 10 cm (3-25cm). Furhter
analysis of other antropometric parameters are underway.
Conclusions: There is a strong body of evidence regarding
the relation between dietary behaviors, body mass index

Safety and efficacy assessment
of immunotherapy in elderly
cancer patients with tumours at
different sites: a single-center
retrospective, observational
study
Liscia N.1, Donisi C.2, Lai E.2, Tolu S.3, Mariani S.2, Balconi F.2,
Pireddu A.3, Camera S.3, Persano M.2, Musio F.2, Impera V.1, Pretta
A.1, Pinna G.2, Spanu D.2, Dubois M.2, Saba G.2, Astara G.2, Atzori
F.2, Madeddu C.2, Massa E.2, Scartozzi M.2
1
Medical Oncology Unit, Sapienza University of Rome-University Hospital
and University of Cagliari, Cagliari, Italy, Cagliari; 2Medical Oncology Unit,
University Hospital and University of Cagliari, Cagliari Italy, Cagliari; 3Medical
Oncology Unit, Sapienza University of Rome-University Hospital and
University of Cagliari, Cagliari Italy, Cagliari

Background: Immunotherapy (IT) is nowadays a validated treatment option for several tumours. As for elderly
patients (pts), there is a lack of data in the literature about
the use of immune checkpoint inhibitors. Elderly pts are
characterized by immunosenescence that may lead to
immunodepression, so IT should be assessed also in this
population. We conducted a retrospective observational
study in pts over 65 receiving IT.
Material (patients) and Methods: We retrospectively
collected clinical data of pts over 65 with different tumour
types treated with IT at the Medical Oncology Unit of
Cagliari University Hospital (March 2016-February 2020).
Our study aimed to assess the safety and efficacy of IT in
the study population. Statistical analysis was performed
with MedCalc (survival distribution: Kaplan-Meier
method; survival curves comparison: log-rank test).
Results: Globally, 33 pts were included in our analysis,
24 males and 9 females; the mean age was 77,4 (range 66
- 88). 82% of pts had multiple comorbidities. 19 pts had
lung cancer, 8 melanoma, 5 kidney cancer, and 1 urothelial cancer. 15 pts received pembrolizumab, 2 atezolizumab and 16 nivolumab. 12,1% of pts showed grade 3
(G3) immunotherapy related adverse events (IrAEs) leading only to temporary IT interruption (1 cutaneous toxicity, 1 arthritis, 1 pneumonia, 1 xerostomia). 42,4% of pts
had G1 and G2 IrAEs (14,3% concomitant G1-G2). 1 of
pts presented arthritis, 5/14 rash, 2/14 hepatitis, and 6/14
thyroiditis. Complete response was observed in 3,03% of
cases, stable disease in 42,4%, partial response in 27,3%,
and progression disease in 27,3% of cases. Within the 31st

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020